104TiP Phase Ib/IIa study of ATR inhibitor tuvusertib + anti-PD-1 cemiplimab in patients with advanced non-squamous (nsq) non-small cell lung cancer (NSCLC) that has progressed on prior anti-PD-(L)1 and platinum-based therapies

Authors:
  • LPL. Paz-Ares
    L. Paz-Ares
  • FCF. Cappuzzo
    F. Cappuzzo
  • NYN. Yamamoto
    N. Yamamoto
  • NVN. Vokes
    N. Vokes
  • JGJ.E. Gray
    J.E. Gray
  • TOT.K. Owonikoko
    T.K. Owonikoko
  • RAR. Ariyasu
    R. Ariyasu
  • HIH. Ishii
    H. Ishii
  • JKJ.H. Kang
    J.H. Kang
  • SLS-H. Lee
    S-H. Lee
  • RHR. Hallwachs
    R. Hallwachs
  • ACA. Coenen-Stass
    A. Coenen-Stass
Open Access
Publisher website
Google Scholar
Abstract
No abstract available